14th July 2022
New therapeutic approach against glioblastoma
In the GLIOTAR joint project, an innovative concept of radiopharmaceutical theranostic drugs is being developed to improve treatment options ...
16th June 2022
Research, test, develop - EPO GmbH has been supporting research and development in pharmacology and oncology for 25 years
EPO GmbH recently celebrated its 25th company anniversary. It all started as a spin-off from the Max Delbrück Center for Molecular Medicine with three employees, today there are 50 and the company for preclinical research ...
21th January 2022
Combination is key – new treatment options for lung and colon cancer?
Patients with advanced colon cancer have limited treatment options as tumors frequently metastasize to the peritoneum or to the liver. Together with the Charité, Alacris, the Max-Plack-Institute for Molecular Genetics in Berlin and ...